Difference between revisions of "Example orders for CHOEP in lymphoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{{:Editing test page 2}}<br>" to "") |
Warner-admin (talk | contribs) m (Text replacement - "6 Gy" to "600 cGy") |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | '''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].''' | + | <!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''--> |
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. | Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. | ||
| Line 16: | Line 16: | ||
*[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV on days days 1-3 | *[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV on days days 1-3 | ||
*[[Prednisone (Sterapred)]] 100 mg PO on days 1 to 5 | *[[Prednisone (Sterapred)]] 100 mg PO on days 1 to 5 | ||
| − | *Patients with initial bulky disease (mass conglomerate at least 7.5 cm) received | + | *Patients with initial bulky disease (mass conglomerate at least 7.5 cm) received 3600 cGy radiation therapy and to extranodal sites of disease when possible |
'''21-day cycles x 6 cycles''' | '''21-day cycles x 6 cycles''' | ||
| − | ====Supportive | + | ====Supportive therapy==== |
*Fosaprepitant (Emend injection) 150 mg IV x1 on day 1 prior to chemotherapy | *Fosaprepitant (Emend injection) 150 mg IV x1 on day 1 prior to chemotherapy | ||
| − | *Ondansetron (Zofran) 8 mg IV 30 minutes prior to chemotherapy | + | *Ondansetron (Zofran) 8 mg IV 30 minutes prior to chemotherapy |
*Allopurinol (Aloprim) as described below | *Allopurinol (Aloprim) as described below | ||
| Line 35: | Line 35: | ||
Outpatient medications: | Outpatient medications: | ||
| − | *[[Acyclovir (Zovirax)]] 400 mg PO | + | *[[Acyclovir (Zovirax)]] 400 mg PO three times per day |
*Allopurinol (Aloprim) 300 mg PO daily | *Allopurinol (Aloprim) 300 mg PO daily | ||
*[[Filgrastim (Neupogen)]] 300 mcg (patient is 63 kg) SC daily on days 4-13 | *[[Filgrastim (Neupogen)]] 300 mcg (patient is 63 kg) SC daily on days 4-13 | ||
| − | *Ondansetron (Zofran) 8 mg PO | + | *Ondansetron (Zofran) 8 mg PO three times per day |
*Pantoprazole (Protonix) 40 mg PO daily | *Pantoprazole (Protonix) 40 mg PO daily | ||
*[[Prednisone (Sterapred)]] as described above | *[[Prednisone (Sterapred)]] as described above | ||
| − | *Docusate (Colace) 100 mg PO | + | *Docusate (Colace) 100 mg PO twice per day prn constipation |
| − | *Sennosides (Senna) 8.6 mg PO | + | *Sennosides (Senna) 8.6 mg PO every 8 hours prn constipation |
'''Clinical scenario & comments:''' | '''Clinical scenario & comments:''' | ||
Latest revision as of 13:05, 1 March 2024
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
CHOEP, CHOPE
CHOEP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Etoposide, Prednisone
Published regimens and references may be found on the Aggressive Non-Hodgkin lymphoma page.
Example regimen #1
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV on day 1
- Doxorubicin (Adriamycin) 50 mg/m2 IV on day 1
- Vincristine (Oncovin) 2 mg IV on day 1
- Etoposide (Vepesid) 100 mg/m2 IV on days days 1-3
- Prednisone (Sterapred) 100 mg PO on days 1 to 5
- Patients with initial bulky disease (mass conglomerate at least 7.5 cm) received 3600 cGy radiation therapy and to extranodal sites of disease when possible
21-day cycles x 6 cycles
Supportive therapy
- Fosaprepitant (Emend injection) 150 mg IV x1 on day 1 prior to chemotherapy
- Ondansetron (Zofran) 8 mg IV 30 minutes prior to chemotherapy
- Allopurinol (Aloprim) as described below
Hydration:
- 500 ml NS and/or D5W KVO rate to be used as running IV for chemotherapy infusion. Give up to 500 ml NS and/or D5W.
Monitoring:
- On days 1, 3, 8, and 17 of cycle 1: CBC with differential, absolute neutrophil count (ANC), comprehensive metabolic panel (chem 10 and LFTs), LDH, uric acid; future labs to be determined based on patient's cycle 1 counts
- Prior to start of therapy, check beta-2 microglobulin, SPEP, IgG, IgA, IgM
- Initial staging with CT torso & bone marrow biopsy
- In anticipation of rituxan use starting cycle 2, check hepatitis B surface antibody (HbsAb), hepatitis B surface antigen (HbsAg), hepatitis B core antibody (HbcAb), hepatitis C antibody (HCV Ab)
Outpatient medications:
- Acyclovir (Zovirax) 400 mg PO three times per day
- Allopurinol (Aloprim) 300 mg PO daily
- Filgrastim (Neupogen) 300 mcg (patient is 63 kg) SC daily on days 4-13
- Ondansetron (Zofran) 8 mg PO three times per day
- Pantoprazole (Protonix) 40 mg PO daily
- Prednisone (Sterapred) as described above
- Docusate (Colace) 100 mg PO twice per day prn constipation
- Sennosides (Senna) 8.6 mg PO every 8 hours prn constipation
Clinical scenario & comments:
- 44 year-old lady with primary mediastinal lymphoma; 7 cm anterior mediastinal mass, ECOG performance status 0.